The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

I tell people I feel blessed to not be diagnosed with cancer in the US. Right now pauses on federal funding, including grants ...

India's Union Budget 2025-26 proposes cutting 7 customs tariff rates for industrial goods, reducing total slabs to 8, ...

Twenty-four-year-old Caitlyn Micholson is fighting cancer and for a chance to access lifesaving alternative treatment that is ...

Panjim: The Goa Health Department, alongside AstraZeneca and Qure.ai, is launching multiple initiatives to improve cancer ...

For many women battling breast cancer, or any other type of cancer, the journey is not just about surviving, but also ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...